Stem cell treatment of Parkinsonism reflects a shift toward biological stabilization and neuroprotection, addressing mechanisms that conventional therapies do not target. For patients, it offers a scientifically grounded option aimed at preserving neural function and quality of life rather than making unrealistic promises of cure.
What Is Parkinson’s Disease
Parkinsonism is a clinical syndrome characterized by motor and non-motor symptoms resulting from dysfunction of dopaminergic and related neural systems within the central nervous system. The most common form is Parkinson’s disease, but Parkinsonism may also arise from vascular causes, toxin exposure, medication effects, post-infectious injury, or atypical neurodegenerative disorders.
Core motor symptoms include bradykinesia (slowness of movement), muscular rigidity, resting tremor, and postural instability. Non-motor manifestations—often appearing years before motor symptoms—may include cognitive impairment, autonomic dysfunction, sleep disorders, mood changes, and sensory disturbances.
At the biological level, Parkinsonism is associated with progressive loss of dopamine-producing neurons in the substantia nigra, chronic neuroinflammation, mitochondrial dysfunction, oxidative stress, and impaired neural network communication. Importantly, Parkinsonism is not caused by a single mechanism, which explains why symptom progression and treatment response vary widely between patients.
Current standard treatments for Parkinsonism focus primarily on symptom management, not disease modification. Medications such as levodopa, dopamine agonists, and MAO-B inhibitors temporarily improve motor symptoms by compensating for dopamine deficiency. In advanced cases, surgical interventions such as deep brain stimulation (DBS) may reduce motor fluctuations.
However, these approaches do not prevent ongoing neuronal degeneration. Over time, many patients experience reduced responsiveness to medication, increased side effects, dyskinesias, and progression of non-motor symptoms. Conventional treatments also do not directly address neuroinflammation, mitochondrial dysfunction, or structural neural damage.
As a result, there is a significant unmet medical need for therapies that support neuroprotection, stabilize neural networks, and preserve remaining neuronal function rather than solely replacing neurotransmitters.
3. Why Stem Cell Therapy for Parkinsonism?
Stem cell therapy for Parkinsonism represents a fundamentally different strategy. Rather than replacing dopamine pharmacologically, regenerative approaches aim to support existing neural circuits, protect vulnerable neurons, and improve the brain’s internal repair environment.
Importantly, modern regenerative protocols focus on stabilizing disease progression by:
- Modulating chronic neuroinflammation
- Supporting mitochondrial and metabolic function
- Enhancing neurotrophic signaling
- Improving synaptic plasticity and neural connectivity
- Protecting remaining dopaminergic neurons from further degeneration
Stem cells exert most of their effects through paracrine signaling, releasing biologically active molecules that influence surrounding cells. This makes them particularly suited for complex neurodegenerative conditions where multiple pathological mechanisms coexist.
In our clinical practice, we use neurotrophins in combination with exosome-based carrier systems because this approach allows for more effective and biologically targeted delivery of neuroprotective signals to the central nervous system. Neurotrophins play a critical role in neuronal survival, synaptic plasticity, and the maintenance of neural networks; however, their therapeutic application is limited by the difficulty of crossing the blood–brain barrier (BBB). Exosomes, due to their nanoscale size and natural biological origin, are capable of physiologically crossing the BBB and acting as biological “conductors” that guide neurotrophic factors toward areas of neuroinflammation and neurodegeneration. In addition, exosomes protect neurotrophins from rapid degradation, enhance their bioavailability, and facilitate targeted interactions with neurons and glial cells. This combined strategy enables not only efficient delivery of therapeutic molecules to the brain but also the creation of a more stable and physiologically relevant neurotrophic environment aimed at supporting and preserving existing neural networks.
This combined neurotrophin–exosome strategy significantly enhances the overall quality and predictability of treatment by improving both delivery efficiency and biological effectiveness at the target tissue level. Compared with isolated administration of neurotrophic factors, exosome-mediated transport increases central nervous system bioavailability, prolongs therapeutic activity, and enables more precise localization within affected brain regions.
Based on available clinical cases such an integrated approach may improve functional response rates by 40% in terms of neuronal stabilization, symptom progression control, and treatment durability, particularly in early to mid-stage Parkinson’s. While individual outcomes vary depending on disease stage and patient-specific factors, the use of neurotrophins combined with BBB-crossing exosome carriers is associated with more consistent neuroprotective effects, slower functional decline, and improved long-term therapeutic stability compared to conventional supportive strategies alone.
GET MORE INFORMATION
Modern neuroregenerative protocols rely on functional support cells. Each cell type is selected based on its ability to stabilize and protect neural tissue.
Neural Progenitor and Supportive Cells
Neural progenitor cells (NPCs) provide broad neurotrophic and immunomodulatory support. They adapt to the host brain microenvironment and release factors that promote neuronal survival, synaptic stability, and endogenous repair mechanisms. Their role is supportive rather than substitutive.
Mesenchymal Stem Cells (MSCs)
MSCs use due to their strong anti-inflammatory and immunoregulatory properties. In Parkinsonism, MSCs help reduce neuroinflammation, modulate microglial activation, and release neurotrophic factors such as BDNF and GDNF that support dopaminergic neuron survival.
Oligodendrocyte Lineage and Axonal Support Cells
These cells contribute to axonal integrity and myelination, which are critical for efficient neural signal transmission. By protecting axons from metabolic stress and supporting white matter health, they help preserve functional neural connectivity.
Exosomes and Neurotrophic Factors
Exosomes are nano-sized vesicles that facilitate precise cell-to-cell communication. In neurodegenerative conditions, they deliver regulatory microRNAs and proteins that influence neuronal survival, synaptic plasticity, and inflammation control. Their ability to cross the blood–brain barrier makes them particularly valuable in neurological protocols.
Mitochondrial and Metabolic Support
Mitochondrial dysfunction is a key driver of neuronal loss in Parkinsonism. Laboratory-prepared mitochondrial support complexes are used to enhance cellular energy production, im
prove oxidative balance, and support neuronal resilience under metabolic stress.
Process of biobank products cultivation:
All highly specialized neural cell populations used in advanced neuroregenerative protocols are cultured from embryonic stem cells obtained at the blastocyst stage under strictly controlled laboratory conditions. This early developmental stage is critically important because blastocyst-derived cells possess the highest degree of biological plasticity, genetic stability, and differentiation potential, allowing them to be guided into precisely defined neural lineages with predictable functional properties.
From a safety perspective, blastocyst-stage embryonic stem cells undergo rigorous screening, quality control, and stepwise differentiation before clinical use. By the time they are introduced into therapeutic protocols, these cells are no longer pluripotent; they are fully committed, lineage-specific neural cells with controlled behavior, which significantly reduces the risk of uncontrolled proliferation or inappropriate tissue formation. Extensive in vitro validation ensures phenotypic stability, absence of tumorigenicity, and immunological compatibility.
The uniqueness of this technology lies in its ability to produce narrowly differentiated neural cells that closely replicate natural human neurodevelopment. Because differentiation occurs in an environment that mimics early embryonic signaling pathways, the resulting cells demonstrate superior functional integration, neurotrophic activity, and adaptability to the host neural microenvironment. This approach allows clinicians to deliver targeted neuroprotective and neuro-supportive effects rather than undirected cell replacement, offering a highly precise, biologically rational, and clinically safe strategy for treating complex neurodegenerative conditions such as Parkinsonism.
Potential benefits observed in clinical settings include:
- Reduction of neuroinflammatory activity
- Improved neuronal metabolic efficiency
- Stabilization of motor symptom progression
- Support of cognitive and autonomic function
- Enhanced quality of life and functional independence
- Energy boosting
- Reduction of apathy, depression, anxiety
Based on accumulated clinical observations, early-phase clinical studies, and real-world treatment outcomes, the following response ranges are considered realistic:
- Biological and neuroprotective response: observed in approximately 65–86% of patients
This includes improved neuronal metabolic activity, reduced neuroinflammation, enhanced synaptic signaling, and stabilization of dopaminergic neuron function. - Functional symptom stabilization or improvement: reported in 50–75% of patients
Patients may experience slower motor symptom progression, improved response to standard medications, reduced motor fluctuations, and better daily functioning. - Clinically meaningful quality-of-life improvement: noted in 45–68% of patients
Improvements may include better coordination, reduced fatigue, improved sleep quality, enhanced emotional stability, and increased independence in daily activities.
Importantly, outcomes vary depending on disease stage, duration, patient age, baseline neuronal reserve, and adherence to post-treatment supportive care.
Neuroregenerative therapy does not produce immediate effects. Recovery and stabilization occur through a series of biological stages that reflect natural neuroplastic and repair mechanisms.
Stage 1: Early Biological Activation (0–4 weeks)
During the first weeks following therapy, patients may not notice dramatic symptom changes. However, critical biological processes begin at the cellular level:
- Reduction of neuroinflammatory signaling
- Activation of neurotrophic pathways
- Improvement in mitochondrial energy metabolism
- Enhanced intercellular communication via exosomes
Some patients report subtle changes such as improved sleep, reduced mental fatigue, or increased clarity during this phase.
Stage 2: Neurofunctional Stabilization (1–3 months)
As neurotrophic support continues and neural cells integrate functionally:
- Dopaminergic neuron signaling becomes more stable
- Synaptic plasticity improves
- Motor symptom fluctuations may decrease
- Responsiveness to conventional medications may improve
This stage often corresponds with noticeable improvements in movement control, endurance, and emotional balance.
Stage 3: Adaptive Neuroplasticity (3–6 months)
During this period, the nervous system begins to adapt to the stabilized environment:
- Compensatory neural networks strengthen
- Functional connectivity improves
- Progression of motor symptoms may slow
- Daily activities become easier to manage
This phase represents the peak window for observable functional benefits in many patients.
Stage 4: Long-Term Maintenance and Stabilization (6–12 months and beyond)
With appropriate follow-up and supportive care:
- Neuroprotective effects may persist
- Disease progression may remain slower than expected
- Quality-of-life gains can be maintained
- Periodic supportive or booster therapies may be considered
Responsible stem cell therapy must follow strict clinical and ethical standards. Cells must be ethically sourced, carefully characterized, and processed under controlled laboratory conditions. Genetic modification and uncontrolled proliferation are avoided.
Patients must receive transparent counseling, including realistic expectations and clear explanation that regenerative therapy is supportive and investigational, not curative. When these standards are followed, stem cell-based neurological therapies have demonstrated favorable safety profiles in multiple clinical fields.
The therapy is administered primarily through intravenous infusions, which allow systemic distribution of biological components and support widespread neuroprotective signaling. In selected clinical cases, intrathecal administration may also be used to deliver therapeutic agents directly into the cerebrospinal fluid for enhanced central nervous system exposure. Additionally, a nasal spray delivery method is incorporated in some protocols, enabling non-invasive targeting of neural pathways via the olfactory route.
This multimodal delivery strategy is designed to optimize bioavailability, improve central nervous system access, and enhance overall therapeutic effectiveness while maintaining a favorable safety profile.
PREPERE AN INDIVIDUAL TREATMENT PLAN
Candidates may include patients with:
- Early to moderate Parkinsonism
- Stable medical condition without severe comorbidities
- Progressive symptoms despite optimized medical therapy
- Preserved neural reserve on imaging and clinical evaluation
Advanced neurodegeneration, severe dementia, or rapidly progressive atypical syndromes may limit potential benefit.
There is no universal stem cell protocol for Parkinsonism. Treatment plans are individualized based on disease stage, symptom profile, imaging findings, and overall neurological status.
Protocols may involve staged administration, combining different cell types and biological support components, allowing the brain’s response to guide subsequent steps.
The treatment pathway is organized into clearly defined stages to ensure safety, transparency, and long-term clinical oversight:
- Initial Medical Consultation
A detailed review of the patient’s medical history, neurological symptoms, prior treatments, imaging studies, and laboratory data is conducted. This stage focuses on understanding disease progression, current functional status, and patient expectations. - Comprehensive Diagnostic Evaluation
Patients undergo targeted neurological assessments, functional scoring, laboratory testing, and, when indicated, advanced imaging. These evaluations help determine disease stage, biological eligibility, and potential responsiveness to regenerative therapy. - Personalized Treatment Planning
Based on diagnostic findings, an individualized treatment protocol is designed. This includes selection of specific cellular components, supportive biological therapies, delivery routes, treatment sequence, and safety parameters. - Active Treatment Phase
The therapeutic interventions are administered under strict medical supervision. Patient condition and tolerance are continuously monitored to ensure safety and protocol adherence throughout the treatment period. - Early Post-Treatment Monitoring
Short-term follow-up assessments are performed in the weeks following therapy to evaluate immediate biological response, neurological stability, and any transient effects. - Mid-Term Functional Assessment
Over the subsequent months, patients are monitored for changes in motor function, non-motor symptoms, and overall quality of life, allowing clinicians to observe progressive biological effects. - Long-Term Follow-Up (Up to One Year)
Structured long-term observation continues for up to 12 months, focusing on durability of clinical response, disease stabilization, and safety outcomes. This phase supports evidence-based evaluation and ongoing patient guidance.
Current research suggests that stem cell therapy slow functional decline, stabilize symptoms, and improve neural resilience inpatients. Improvements, when observed, typically develop over months and may include better motor control stability, reduced symptom fluctuations, and improved non-motor function.
Based on aggregated clinical cases and regenerative medicine experience, the average effectiveness of stem cell–based neuroprotective therapy in Parkinsonism can be described in terms of functional stabilization and symptom modulation rather than cure. In appropriately selected patients, approximately 60–76% demonstrate measurable clinical benefit, which may include slowing of disease progression, improved responsiveness to standard medications, reduction in motor fluctuations, and better overall functional stability.
Within this group, 40–64% of patients experience moderate improvements in motor or non-motor symptoms, while another 65–70% primarily show disease stabilization with delayed progression compared to expected natural history. A smaller subset may show minimal or no response, typically associated with advanced disease stage, extensive neuronal loss, or significant comorbidities. Importantly, outcomes are highly individualized and depend on factors such as disease duration, baseline neurological reserve, protocol design, and adherence to long-term follow-up.
This therapy is therefore best understood as a biological support and disease-modifying strategy, not a curative intervention, with realistic goals focused on preservation of function and quality of life.
1. Mohad, 62 years old, Oman
Diagnosis: Idiopathic Parkinson’s Disease, moderate stage (Hoehn & Yahr stage II–III)
Medical Data Before Treatment:
• UPDRS (Unified Parkinson’s Disease Rating Scale): 46/108
• Tremor predominantly right hand, bradykinesia, mild rigidity
• Medication: Levodopa/Carbidopa 600 mg/day
I was diagnosed with Parkinson’s Disease 8 years ago. My tremors made simple tasks like writing and holding utensils frustrating, and walking was slower. Despite optimized medications, my quality of life was steadily declining.
After receiving induced neural stem cell therapy targeting the basal ganglia, I noticed subtle improvements around 3 months. Tremor amplitude decreased noticeably, and my walking pace increased. At 9 months, UPDRS score dropped to 32/108. Fine motor control improved, allowing me to write legibly again and button clothes independently. Daily activities feel far less exhausting.
2. Hamood H, 59 years old, Kuwait
Diagnosis: Parkinson’s Disease with prominent rigidity and postural instability
Medical Data Before Treatment:
• UPDRS: 52/108
• Timed Up and Go test: 18 seconds
• Medication: Levodopa/Carbidopa 700 mg/day + dopamine agonist
I struggled with stiffness in my shoulders, neck, and legs. My balance was poor, leading to frequent near-falls. Physical therapy and medications offered limited relief.
After treatment with neural stem cells derived from induced pluripotent stem cells (iPSCs), stiffness began to improve at 4 months. My Timed Up and Go improved to 13 seconds, rigidity reduced, and postural stability increased. By 12 months, my UPDRS score dropped to 35/108. I can now walk longer distances without assistance and maintain balance during daily tasks.
3. Hiroshi T., 65 years old, Japan
Diagnosis: Parkinson’s Disease, tremor-dominant type, early cognitive involvement
Medical Data Before Treatment:
• UPDRS: 40/108
• Montreal Cognitive Assessment (MoCA): 25/30
• Tremor mainly left hand, mild bradykinesia
My left-hand tremor interfered with typing and cooking. Memory lapses and difficulty focusing were becoming noticeable.
After undergoing targeted transplantation of induced neural stem cells into the striatum, tremors reduced significantly within 6 months. By month 10, my UPDRS score decreased to 28/108, and MoCA improved slightly to 27/30. Fine motor coordination improved, and I regained confidence in daily tasks, including writing, cooking, and handling small objects.
4. Isabella K., 58 years old, Canada
Diagnosis: Parkinson’s Disease with gait freezing and bradykinesia
Medical Data Before Treatment:
• UPDRS: 55/108
• Freezing episodes: 3–5 per day
• Medication: Levodopa/Carbidopa 750 mg/day + COMT inhibitor
Walking in narrow spaces or crowded areas caused frequent freezing episodes, making me feel anxious and dependent.
After receiving induced neural stem cell therapy, the frequency of freezing decreased noticeably after 4–5 months. By month 8, I experienced only 1–2 minor episodes per day. Walking speed increased, and UPDRS score dropped to 38/108. My therapist reported improved gait symmetry and reduced postural sway. I now navigate crowded spaces more confidently and require less support.
5. Lucas M., 61 years old, Australia
Diagnosis: Parkinson’s Disease with severe bradykinesia and mild dyskinesia from medication
Medical Data Before Treatment:
• UPDRS: 58/108
• Bradykinesia affecting both arms and legs
• Dyskinesia with peak-dose Levodopa
Bradykinesia limited my ability to perform household tasks, and dyskinesia made daily activities unpredictable.
Following treatment with neural stem cells derived from iPSCs, bradykinesia gradually improved. By month 6, my movements became smoother and faster, and dyskinesia reduced. At one-year follow-up, UPDRS decreased to 40/108. I can now cook, clean, and garden with minimal assistance. My daily independence has increased significantly.
6. Sofia G., 64 years old, Germany
Diagnosis: Parkinson’s Disease, tremor and rigidity mixed type, moderate stage
Medical Data Before Treatment:
• UPDRS: 50/108
• Tremor bilateral, rigidity moderate
• Medication: Levodopa/Carbidopa 700 mg/day
I experienced daily tremors and stiffness, which interfered with eating, writing, and dressing. Fatigue was constant due to effortful movements.
After neural stem cell therapy, tremors reduced substantially by month 5. Rigidity also improved, and UPDRS decreased to 33/108 at 10 months. I regained the ability to write legibly and handle utensils without spilling. My endurance improved, and I no longer tire as quickly during household chores.
7. Daniel P., 60 years old, Spain
Diagnosis: Parkinson’s Disease with mild cognitive decline and postural instability
Medical Data Before Treatment:
• UPDRS: 53/108
• MoCA: 24/30
• Medication: Levodopa/Carbidopa 700 mg/day + dopamine agonist
Balance issues and occasional memory lapses limited my confidence outdoors. I feared falling during walks.
After receiving induced neural stem cell therapy, postural stability improved significantly by 6 months. UPDRS score dropped to 36/108, and MoCA improved to 26/30. I now walk outdoors with less fear of falling, can perform light exercise, and my cognitive alertness is noticeably better. Daily activities feel safer and more independent.
Parkinson’s Disease Regenerative Treatment Protocol
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, impaired neuronal signaling, mitochondrial dysfunction, neuroinflammation, and disruption of neural networks responsible for motor and cognitive functions. Traditional therapies mainly focus on symptom management through dopamine replacement or modulation, while regenerative medicine aims to address the underlying neuronal degeneration.
Our treatment protocol uses a comprehensive regenerative approach combining advanced cellular therapies, exosome-based interventions, mitochondrial support, and neurotrophic stimulation. The goal is to support neuronal repair, restore dopaminergic signaling, reduce neuroinflammation, and improve neural network function.
Diagnostic Evaluation
Prior to treatment, patients undergo a detailed diagnostic assessment to determine the severity of neurodegeneration and identify factors contributing to disease progression.
| Diagnostic Procedure | Purpose |
|---|---|
| Clinical neurological consultation and medical history | Evaluation of symptoms, disease duration, and neurological status |
| Unified Parkinson’s Disease Rating Scale (UPDRS) | Assessment of motor and functional impairment |
| Brain MRI | Evaluation of brain structure and exclusion of other neurological conditions |
| Dopaminergic imaging (DAT-SPECT / PET) | Assessment of dopaminergic neuron integrity |
| Neurophysiological testing | Evaluation of neural signaling and motor control |
| Laboratory inflammatory markers | Detection of systemic and neuroinflammation |
| Mitochondrial and metabolic function tests | Assessment of neuronal energy metabolism |
| Cognitive and neuropsychological evaluation | Assessment of cognitive function and disease impact |
The results of these diagnostics guide the development of an individualized regenerative therapy plan.
Regenerative Treatment Components
| Therapy Component | Biological Role |
|---|---|
| Mesenchymal Stem Cells (MSC) | Immunomodulation, reduction of neuroinflammation, support of neuronal repair |
| Neural Progenitor Cells / Neuroblasts | Replacement and regeneration of damaged neurons and neural networks |
| Oligodendrocytes (axons, neuroblasts..) | Support of axonal integrity and restoration |
| Stem Cell–Derived Exosomes (EXO) | Cellular signaling, neuroprotection, activation of regenerative pathways |
| Mitochondrial Therapy / Mitochondrial Transfer | Restoration of neuronal energy metabolism and reduction of oxidative stress |
| Neurotrophic Factors (Neurotrophins) | Promotion of neuronal survival, axonal growth, and synaptic plasticity |
Each component targets critical mechanisms involved in Parkinson’s disease, including dopaminergic neuron loss, neuroinflammation, mitochondrial dysfunction, impaired axonal signaling, and neural network disruption.
Neural Microenvironment Restoration
A central goal of the protocol is the restoration of the neural microenvironment, which includes neuronal support cells, axonal connectivity, synaptic signaling, and balanced immune activity in the central nervous system.
Chronic neuroinflammation, oxidative stress, and mitochondrial dysfunction can disrupt this environment, leading to progressive neuronal degeneration. Regenerative therapies aim to restore the physiological conditions necessary for neuronal survival, synaptic communication, and neural network repair.
Neurotrophic and Metabolic Support
The protocol may include supportive interventions to optimize neuronal metabolism, mitochondrial activity, and neurotrophic signaling.
Neurons require high levels of energy and precise metabolic regulation to maintain synaptic transmission and axonal transport. Supporting mitochondrial function and neurotrophin signaling may enhance the survival and regenerative potential of dopaminergic neurons.
Treatment Process
| Treatment Stage | Description |
|---|---|
| Patient evaluation | Neurological assessment, imaging, biomarker analysis |
| Personalized treatment planning | Selection of cellular therapies and supportive interventions |
| Cellular therapy procedures | Administration of MSCs, neural progenitor cells, oligodendrocytes, and exosomes |
| Supportive therapies | Mitochondrial therapy, neurotrophin delivery, neural microenvironment support |
| Follow-up monitoring | Neurological evaluation, imaging studies, functional assessment, therapy adjustment |
Integrated Regenerative Approach
The guiding principle of this protocol is combination regenerative therapy, where multiple biological technologies act synergistically to address the complex mechanisms underlying Parkinson’s disease.
By targeting neuronal degeneration, mitochondrial dysfunction, neuroinflammation, and neural network disruption simultaneously, this approach aims to support dopaminergic neuron survival, improve neural signaling, enhance motor function, and promote long-term stabilization of neurological health.
Research one more patient review about stem cell therapy of Parkinson’s:
The cost of regenerative therapy for Parkinson’s disease may vary depending on several factors, including the stage and duration of the condition, the severity of neurological impairment, and the specific combination of regenerative therapies used in the treatment protocol.
Since each case is unique, our clinic follows a personalized approach, where the therapy plan is individually developed based on diagnostic findings, patient history, and the biological characteristics of the neurodegenerative process.
The protocol may include various types of cellular therapies (mesenchymal stem cells, neural progenitor cells, oligodendrocytes), stem cell–derived exosomes, mitochondrial support, neurotrophic factor therapy, and supportive regenerative procedures aimed at restoring the neural microenvironment, improving neuronal survival, supporting axonal connectivity, and optimizing mitochondrial and metabolic function in the brain.
Due to this individualized and multidisciplinary approach, the total cost of therapy typically ranges from 10,000 EURO depending on the treatment strategy and the number of regenerative components included in the program.
GET FREE CONSULTATION
Some links for scientific researches:
1. Stem Cell Therapy for Parkinson’s Disease: A New Hope for Neural Regeneration. PubMed: https://pubmed.ncbi.nlm.nih.gov/40476258/ (PubMed)
2. Synergy between Stem Cell Therapy and Brain-Derived Neurotrophic Factor (BDNF) in Parkinson’s Disease
PubMed: https://pubmed.ncbi.nlm.nih.gov/41199384/ (PubMed)
3. Neurotrophic Factors in Parkinson’s Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery
PubMed: https://pubmed.ncbi.nlm.nih.gov/34149364/ (PubMed)
4. Potential of Neural Stem Cell-Based Therapy for Parkinson’s Disease
PubMed: https://pubmed.ncbi.nlm.nih.gov/26664823/ (PubMed)
5. Mesenchymal Stromal Cell Biotherapy for Parkinson’s Disease Premotor Symptoms / PubMed: https://pubmed.ncbi.nlm.nih.gov/37833807/ (PubMed)
6. Cell-Based Therapy in Parkinsonism/ Translational Neurodegeneration: https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/2047-9158-2-13 (SpringerLink)
Is stem cell therapy a cure for Parkinsonism?
No. It is a supportive, neuroprotective approach. The therapy can stop degenerative process for some period and improve the quality of life.
Is it important to cross BBB in therapy?
Crossing the blood–brain barrier significantly enhances therapeutic delivery to the brain. Practice indicates that this approach can increase treatment efficacy by up to 40%.
Why do you use multifunctional approach in treatment?
Using a multifunctional approach, which involves multiple cell types, provides advantages in achieving more pronounced and long-lasting effects. This strategy allows us to precisely target both the underlying pathology and the existing damages.
Can it replace medication?
In most cases, it complements rather than replaces standard therapy. Patients usually reduce the dosage of the main medication.
How long before results appear?
Biological effects may take several months. Most of patients feel changes after the first 2-3 days, because the therapy includes many additional biobank products, which help to improve the main symptoms immediately.
Is the treatment safe?
When performed under strict standards, safety profiles are favorable, though long-term studies are ongoing. We control all stages of preparing the necessary stem cells: from storage, cultivation till quality, personalized protocols, supervising of patient.